2005 Annual Meeting | Mitochondrial Disorders in Neurology

Date Sunday 04/10/05

Time 06:00 PM - 09:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Dinner Seminar

Director(s) Salvatore DiMauro, MD

Topic(s) Neurogenetics/Neurometabolic Disorders/Neurotoxicology

Learning Objectives Upon completion:
Participants should become familiar with recent progress in mitochondrial genetics and better understand the relationships, which are not always straightforward between mutations in either the nuclear or the mitochondrial genome and clinical presentations. Participants should also gain useful clues to the correct diagnosis of these protean clinical disorders and a realistic understanding of the present limitations but more hopeful future perspectives to therapy.

CME Available No CME available

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident, Other

Event Timeline
06:00 PM - 09:00 PM		Dinner
06:15 PM - 07:00 PM		Mitochondrial Genetics Eric A. Schon, PhD
07:00 PM - 07:10 PM		Questions and Answers Eric A. Schon, PhD
07:10 PM - 07:55 PM		Mitochondrial Diseases Michio Hirano, MD, FAAN
07:55 PM - 08:05 PM		Questions and Answers Michio Hirano, MD, FAAN
08:05 PM - 08:50 PM		Therapeutic Strategies Salvatore DiMauro, MD
08:50 PM - 09:00 PM		Questions and Answers Salvatore DiMauro, MD

Faculty Disclosures
Salvatore DiMauro, MD	No disclosure on file
Eric A. Schon, PhD	Dr. Schon has nothing to disclose.
Michio Hirano, MD, FAAN	Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Modis Therapeutics (a subsidiary of Zogenix). Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Epirium Bio. Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Innovation Specialist. Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precision Biosciences. Dr. Hirano has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Platform Q Health. Dr. Hirano has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Hirano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Stealth Biotherapeutics. The institution of Dr. Hirano has received research support from Modis Therapeutics (a subsidiary of Zogenix. The institution of Dr. Hirano has received research support from Cyclerion. Dr. Hirano has received research support from Reneo Pharmaceuticals. The institution of Dr. Hirano has received research support from Astellas. Dr. Hirano has received intellectual property interests from a discovery or technology relating to health care. Dr. Hirano has received intellectual property interests from a discovery or technology relating to health care. Dr. Hirano has received personal compensation in the range of $0-$499 for serving as a Study Section Reviewer with NIH. Dr. Hirano has a non-compensated relationship as a Research Advisory Board member with Muscular Dystrophy Association that is relevant to AAN interests or activities. Dr. Hirano has a non-compensated relationship as a Scientific and Medical Advisory Board member with United Mitochondrial Disease Foundation that is relevant to AAN interests or activities. Dr. Hirano has a non-compensated relationship as a Scientific Advisory Board member with Barth Syndrome Foundation that is relevant to AAN interests or activities.